Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
May 27 (Reuters) - Tvardi Therapeutics Inc TVRD.O:
TVARDI THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TTI-101 IN IDIOPATHIC PULMONARY FIBROSIS
TVARDI THERAPEUTICS INC - TOPLINE DATA FROM REVERT IPF TRIAL EXPECTED IN Q4 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.